CLDX Overview
Upcoming Projects (CLDX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CLDX)
-
Third View: Discussing the general landscape for treatment of urticaria (hives).
Tickers: NVS, REGN, CLDX
Executed On: Feb 26, 2025 at 03:00 PM EST -
Second View: Discussing the general landscape for treatment of urticaria (hives).
Tickers: NVS, REGN, CLDX
Executed On: Feb 24, 2025 at 04:00 PM EST -
Discussing the general landscape for treatment of urticaria (hives).
Tickers: NVS, REGN, CLDX
Executed On: Feb 24, 2025 at 01:00 PM EST -
A third look: Discussion of barzolvolimab in CSU and CIU
Ticker: CLDX
Executed On: Nov 18, 2024 at 01:00 PM EST -
A second look: Discussion of barzolvolimab in CSU and CIU
Ticker: CLDX
Executed On: Nov 18, 2024 at 11:30 AM EST -
Discussion of barzolvolimab in CSU and CIU
Ticker: CLDX
Executed On: Nov 15, 2024 at 01:00 PM EST -
A third look: Discussing the recent phase 2 data of barzolvolimab in two of the most common forms of CIndU - Cold Urticaria and symptomatic dermographism
Ticker: CLDX
Executed On: Aug 02, 2024 at 12:00 PM EDT -
A second look: Discussing the recent phase 2 data of barzolvolimab in two of the most common forms of CIndU - Cold Urticaria and symptomatic dermographism
Ticker: CLDX
Executed On: Aug 01, 2024 at 12:00 PM EDT -
Discussing the recent phase 2 data of barzolvolimab in two of the most common forms of CIndU - Cold Urticaria and symptomatic dermographism
Ticker: CLDX
Executed On: Aug 01, 2024 at 09:00 AM EDT -
A Third Opinion: Looking into the recent 12 week results of Barzolvolimab improving angioedema in patients with chronic spontaneous urticaria.
Ticker: CLDX
Executed On: Jun 28, 2024 at 02:00 PM EDT -
A Second Opinion: Looking into the recent 12 week results of Barzolvolimab improving angioedema in patients with chronic spontaneous urticaria.
Ticker: CLDX
Executed On: Jun 28, 2024 at 12:30 PM EDT -
Looking into the recent 12 week results of Barzolvolimab improving angioedema in patients with chronic spontaneous urticaria.
Ticker: CLDX
Executed On: Jun 21, 2024 at 03:00 PM EDT -
A Third Opinion: Looking into the recent 12 week results from the phase 2 clinical trial of Barzolvolimab in patients with chronic spontaneous urticaria.
Ticker: CLDX
Executed On: Mar 18, 2024 at 01:30 PM EDT -
A Second Opinion: Looking into the recent 12 week results from the phase 2 clinical trial of Barzolvolimab in patients with chronic spontaneous urticaria.
Ticker: CLDX
Executed On: Feb 28, 2024 at 04:15 PM EST -
Looking into the recent 12 week results from the phase 2 clinical trial of Barzolvolimab in patients with chronic spontaneous urticaria.
Ticker: CLDX
Executed On: Feb 28, 2024 at 12:00 PM EST -
A third look at the positive top-line results from the Phase 2 Study of barzolvolimab in chronic spontaneous urticaria.
Ticker: CLDX
Executed On: Nov 29, 2023 at 12:30 PM EST -
A second look at the positive top-line results from the Phase 2 Study of barzolvolimab in chronic spontaneous urticaria.
Ticker: CLDX
Executed On: Nov 21, 2023 at 09:30 AM EST -
A look at the positive top-line results from the Phase 2 Study of barzolvolimab in chronic spontaneous urticaria.
Ticker: CLDX
Executed On: Nov 09, 2023 at 03:00 PM EST -
A third look: Discussing the updated Phase 1B data for Celldex' barzolvolimab in chronic spontaneous urticaria (CSU) with an allergist
Ticker: CLDX
Executed On: Mar 22, 2023 at 09:00 AM EDT -
A second look: Discussing the updated Phase 1B data for Celldex' barzolvolimab in chronic spontaneous urticaria (CSU) with an allergist
Ticker: CLDX
Executed On: Mar 09, 2023 at 12:00 PM EST -
Discussing the updated Phase 1B data for Celldex' barzolvolimab in chronic spontaneous urticaria (CSU) with an allergist
Ticker: CLDX
Executed On: Mar 09, 2023 at 10:00 AM EST -
A second look: Discussing Chronic Spontaneous Urticaria, and Celldex's lead product: CDX-0159 - a unique mast cell depleting antibody; KIT Antagonist mAb.
Ticker: CLDX
Executed On: Jul 20, 2022 at 01:00 PM EDT -
Discussing Chronic Spontaneous Urticaria, and Celldex's lead product: CDX-0159 - a unique mast cell depleting antibody; KIT Antagonist mAb.
Ticker: CLDX
Executed On: Jul 14, 2022 at 03:30 PM EDT
Upcoming & Overdue Catalysts (CLDX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (CLDX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
